| Literature DB >> 35126718 |
Alexandru Herdea1,2, Alexandra Struta2, Răzvan Petru Derihaci3, Alexandru Ulici1,2, Adrian Costache2, Florentina Furtunescu2, Alexandra Toma4, Adham Charkaoui4.
Abstract
In recent years, platelet-rich plasma (PRP) therapy has been a subject of controversy in orthopedics field. Our objective was to assess the efficiency of PRP therapy for patients who have suffered grade 2 meniscal lesions and grade 2 anterior cruciate ligament (ACL) lesions, graded by magnetic resonance imaging (MRI). A retrospective observational study was conducted, which included 72 young recreational athletes who had been diagnosed with grade 2 meniscal injury, graded using MRI, that benefited from PRP therapy as an enhancement of the primary treatment, after cast immobilization. The Lysholm score, the pain intensity and the resuming of the physical activity before the PRP treatment and one month after were analyzed. Our study revealed that patients had an improved subjective perception of pain after PRP therapy and an improvement of the Lysholm score. Concurrently, 83.3% of patients could return to sports and daily physical activity. It can be concluded that PRP therapy is a safe, easy to manage treatment, efficient for pain relief and in resuming of sports activities for young recreational athletes who have sustained partial meniscal or ACL tears. In terms of pain relief, it appears that the PRP therapy could be more efficient for young patients with ACL injuries. Copyright: © Herdea et al.Entities:
Keywords: anterior cruciate ligament; knee; meniscus; platelet-rich plasma therapy; sports; young
Year: 2022 PMID: 35126718 PMCID: PMC8796279 DOI: 10.3892/etm.2022.11139
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Growth factors and their cellular effects.
| Growth factor | Cellular effect |
|---|---|
| TGF-β1 | Enhances the proliferative activity of fibroblasts |
| FGF-2 | Promotes angiogenesis, cell migration, cell differentiation and extracellular matrix production |
| IGF-1 | Has a chemotactic effect on myoblasts and fibroblasts |
| PDGF | Stimulates the proliferation and chemotaxis of mesenchymal cells |
| VEGF | Has a chemotactic effect on macrophages and granulocytes; promotes angiogenesis |
TGF-β1, transforming growth factor-β1; FGF-2, fibroblast growth factor-2; IGF-1, insulin-like growth factor, PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.
Figure 1Patient distribution regarding age and sex.
Comparison of pain and Lysholm score before and after PRP.
| Variable | Before PRP N=72 | One month after PRP N=72 | Unpaired sample t-test | Before PRP N=72 |
|---|---|---|---|---|
| Pain (NRS), mean value ± SEM, N | 7.819±0.1599 | 2.22±0.2714 | 5.59 P=0.0065 | 7.819±0.1599 |
| Lysholm score, mean value ± SEM, N | 43.90±2.244 | 85.64±2.152 | 41.73±3.109 P=0.0004 | 43.90±2.244 |
PRP, platelet-rich plasma; NRS, numeric rating scale; SEM, standard error of the mean.
Pain (NRS), Lysholm score variations: ACL lesions vs. meniscal lesions.
| Variable | ACL lesions, N=17 | Meniscal lesions, N=55 | Unpaired sample t-test difference | P-value |
|---|---|---|---|---|
| Pain (NRS) before PRP, mean ± SEM | 7.58±0.32 | 7.89±0.18 | 0.31±0.37 | 0.63 |
| Pain (NRS) after PRP, mean ± SEM | 1.58±0.30 | 2.41±0.36 | 0.82±0.45 | 0.07 |
| Pain (NRS) level decrease (before/after PRP) ± SEM | 6±0.41 N=17 | 5.57±0.36 | -0.52±0.54 | 0.08 |
| Lysholm score before PRP, mean ± SEM | 46.11±4.47 | 43.21±2.60 | -2.89±5.31 | 0.09 |
| Lysholm score after PRP, mean ± SEM | 90±1.76 | 84.29±2.74 | -5.73±3.22 | 0.08 |
| Lysholm score increase (before/after PRP), mean ± SEM | 43.88±4.76 | 41.07±3.32 | -2.80±6.55 | 0.60 |
NRS, numeric rating scale; PRP, platelet-rich plasma; SEM, standard error of the mean; ACL, anterior cruciate ligament.